Skip to content
  • Home
  • News & Events
  • Careers
  • Resources
    • Azurity Code of Conduct
    • Azurity Solutions
    • Azurity Solutions – Patient Direct
    • E-Z Rx®
    • Patient Support
    • Compliance
    • Medical Information
    • Patents & Trademarks
  • Contact Us
Azurity Pharmaceuticals
  • Company
    • About Us
    • Management Team
    • Board of Directors
  • Products
    • Products
    • Anti-Infective
      • FIRVANQ®
    • Cardiovascular/Cardiology
      • BiDil®
      • EDARBI®
      • EDARBYCLOR®
      • EPANED®
      • KATERZIA®
      • QBRELIS®
      • SOTYLIZE®
    • Central Nervous System/Cerebrovascular
      • EPRONTIA®
      • EVEKEO®
      • FLEQSUVY®
      • HORIZANT®
      • NYMALIZE®
      • ZENZEDI®
      • ZONISADE®
    • Endocrinology
      • ADTHYZA®
      • AZMIRO™
      • THYQUIDITY™
      • TRIPTODUR®
    • Gastrointestinal
      • KONVOMEP®
    • Immunology
      • MYHIBBIN™
    • Oncology
      • DANZITEN™
      • GLIADEL® Wafer
      • VIVIMUSTA®
      • XATMEP®
    • Certain products listed may be owned by a subsidiary of Azurity Pharmaceuticals.
  • FIRST Kits
  • Pipeline
Select Page

AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF
DANZITEN™ (nilotinib) tablets, THE FIRST AND ONLY NILOTINIB WITH NO MEALTIME RESTRICTIONS

by GOT | Nov 14, 2024 | News

AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF DANZITEN™ (nilotinib) tablets, THE FIRST AND ONLY NILOTINIB WITH NO MEALTIME RESTRICTIONS WOBURN, Mass. Nov 14, 2024 – Azurity Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has...

Recent Posts

  • AZURITY PHARMACEUTICALS, INC. ANNOUNCES AVAILABILITY OF
    AZMIRO™ (testosterone cypionate) injection for intramuscular use, CIII
  • AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF
    DANZITEN™ (nilotinib) tablets, THE FIRST AND ONLY NILOTINIB WITH NO MEALTIME RESTRICTIONS
  • AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF
    NYMALIZE® (NIMODIPINE) ORAL SOLUTION 30 MG/5 ML PREFILLED ENFIT® SYRINGE
  • AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF
    MYHIBBIN™ (mycophenolate mofetil oral suspension)
  • Azurity Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of
    Zenzedi® (dextroamphetamine sulfate tablets, USP) 30 mg Due to a Mislabeled Package During Manufacturing

Recent Comments

    Archives

    • December 2024
    • November 2024
    • September 2024
    • May 2024
    • January 2024
    • September 2023
    • October 2022
    • September 2022
    • July 2022
    • February 2022
    • November 2021
    • September 2021
    • August 2021
    • February 2021
    • August 2020
    • July 2019
    • April 2018

    Categories

    • CutisPharma Press Releases
    • Legacy Arbor Archives
    • News

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Home

    Pipeline

    Contact Us

    Company

    • About Us
    • Management Team
    • Board of Directors
    • Follow

    Products

    • ADTHYZA®
    • AZMIROTM
    • BIDIL®
    • DANZITEN™
    • EDARBI®
    • EDARBYCLOR®
    • EPANED®
    • EPRONTIA®
    • EVEKEO®
    • FIRVANQ®
    • FLEQSUVY®
    • GLIADEL® Wafer
    • HORIZANT®
    • KATERZIA®
    • KONVOMEP®
    • MYHIBBINTM
    • NYMALIZE®
    • QBRELIS®
    • SOTYLIZE®
    • THYQUIDITYTM
    • TRIPTODUR®
    • VIVIMUSTA®
    • XATMEP®
    • ZENZEDI®
    • ZONISADE®

    Resources

    • Azurity Code of Conduct
    • Azurity Solutions
    • Azurity Solutions – Patient Direct
    • E-Z Rx®
    • Patient Support
    • Compliance
    • Medical Information
    • FIRST Kits
    • Patents & Trademarks
    • Terms of Use
    • Privacy Policy and Cookie Notice
    • Web Accessibility Policy
    • Social Media Global Community Guidelines
    • Social Media Medical Community Guidelines

    Product labeling, packaging, and imagery are for representation purposes only and shall constitute the property of Azurity and all applicable affiliates. The Information contained herein, including product information, is intended only for residents of the United States.

    © 2019 - 2025 Azurity Pharmaceuticals, Inc. All Rights Reserved. All Trademarks referred to are the property of their respective owners. PP-AZ-US-0064
    AZ_Logo_White
    ADA Site Compliance-Accessibility Policy

    NOW AVAILABLE

    Azmiro_logo
    LEARN MORE
    PP-AZO-US-0034

    NOW FDA APPROVED!

    Available Soon for Your Patients


    Learn More
    PP-DAN-US-0042

    Sign Up for Email Updates

    Share your email to receive information about AZURITY® and new hypothyroidism resources.

    *Fields are required

    Terms and conditions

    By clicking Submit, you agree to receive product and disease state information from Azurity

    All personal information will be kept confidential and will not be shared with any parties other than Azurity Pharmaceuticals, Inc. and Spectrum Science Communications, Inc.

    I accept(Required)

    †Terms and Conditions must be accepted before submission.

    Learn More About AZURITY®

    Learn more about how AZURITY may benefit your patients.

    *Fields are required.

    Terms and conditions

    By clicking Submit, you agree to receive product and disease state information from Azurity Pharmaceuticals, Inc. All personal information will be kept confidential and will not be shared with any parties other than Azurity Pharmaceuticals, Inc. and Spectrum Science Communications, Inc.

    I Accept(Required)

    †Terms and Conditions must be accepted before submission.